首頁 > 市場調查報告書 > 製藥

奈米技術 DDS

市場調查報告書

商品編碼

1607745

奈米醫藥的全球市場:模式·用途·適應症·分子類型·不同地區的預測 (～2032年)

Global Nanomedicine Market Research Report: Information by Modality, by Application, and by Indication, by Molecule Type, and by Region Forecast till 2032

出版日期: 2024年11月21日 | 出版商:

Market Research Future | 英文 149 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球奈米藥物市場規模將從2023年的2,529.7億美元成長到2024年的2,737.9億美元，預測期內複合年增長率為12.48%，到2032年將成長到8,198.4億美元。這一規模美元。

全球各種疾病發生率的增加以及與奈米醫學產品開發相關的各種協議推動了市場的發展。

按地區劃分，由於癌症患者患病率上升以及強大的研發基礎設施，北美市場在2023年佔據最大的市場佔有率，超過38.14%。 2020 年，美國報告了 1,603,844 例新癌症病例和 602,347 例癌症死亡病例。每10萬人新增癌症病例403例，癌症死亡144例。

由於奈米技術的進步和改善醫療保健的潛力，歐洲市場正在快速成長。該市場致力於用於監測、治療和診斷的奈米級材料和技術的開發和應用，並且該市場受到個人化治療需求不斷增長和慢性病患病率上升的推動。由於其高昂的研發成本和優良的醫療基礎設施，歐洲處於奈米醫學突破的最前線。重點領域包括標靶藥物傳輸系統、更好的癌症治療和奈米級成像工具。

亞太地區也在快速成長，反映出人們對尖端醫療技術的興趣和投資不斷增加。由於多種因素，包括醫療保健需求的增加、慢性病的流行以及奈米技術研究的重大進展，預計該市場將繼續快速成長。

本報告提供全球奈米醫藥的市場調查，市場定義和概要，市場成長的各種影響因素分析，市場規模的轉變·預測，各種區分·地區/各主要國家的明細，競爭環境，主要企業簡介等資訊。

Global Nanomedicine Market Research Report: Information by Modality (Treatments and Diagnostics), by Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants), and by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others), by Molecule Type (Nanoparticles [Albumin Particles, Inorganic Nanoparticles, Lipid Nanoparticle, Liposomes, and Others], Nanoshells, Nanotubes, and Nanodevices), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

In 2023, the nanomedicine market was estimated at USD 252.97 billion. The Nanomedicine Market is expected to expand from USD 273.79 billion in 2024 to USD 819.84 billion by 2032, with a compound yearly growth rate (CAGR) of 12.48% over the forecast period (2024-2032).

The global market is being driven by increasing occurrences of various ailments around the world, as well as agreements related to nanomedicine product development.

Market Segment insights

The Nanomedicine Market is divided into two segments: treatments and diagnostics.

The Nanomedicine Market is divided into five applications: drug delivery, diagnostic imaging, vaccinations, regenerative medicine, and implants.

The Nanomedicine Market has been classified by indication: oncological illnesses, infectious diseases, cardiovascular diseases, orthopedic disorders, neurological diseases, urological diseases, ophthalmological diseases, immunological diseases, and others.

The Nanomedicine Market is divided into four segments based on molecule type: nanoparticles, nanoshells, nanotubes, and nanodevices.

Regional insights

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America held the biggest market share of more than 38.14% in 2023, owing to the rising prevalence of cancer cases and a strong research and development infrastructure. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer deaths. There were 403 new cancer cases reported per 100,000 people, with 144 people dying from cancer.

The market for nanomedicine in Europe is rapidly developing as a result of advances in nanotechnology and its potential to improve healthcare. This market covers the development and application of nanoscale materials and technologies for monitoring, therapy, and diagnostics. The market is developing as a result of increased demand for tailored therapy and the rising prevalence of chronic diseases. Europe is at the forefront of nanomedicine breakthroughs, thanks to its high R&D spending and excellent healthcare infrastructure. Targeted drug delivery systems, better cancer therapies, and nanoscale imaging tools are key areas of focus.

The Asia-Pacific nanomedicine industry is rapidly developing, reflecting the region's increased interest and investment in cutting-edge healthcare technology. The market is predicted to grow fast due to several factors, including increased healthcare demand, rising chronic illness prevalence, and significant advances in nanotechnology research.

Major Players

Sanofi (France), Johnson & Johnson Services, Inc. (US), Parvus Therapeutics Inc. (US), Nanobiotix (France), Ascendia Pharmaceuticals (US), Bristol-Myers Squibb Company (US), Jazz Pharmaceuticals (Ireland), Cytimmune Sciences, Inc. (US), Nanospectra Biosciences (US), and Pfizer, Inc. (US) are among the key companies in the nanomedicine market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF VARIOUS DISEASES ACROSS THE GLOBE
- 4.2.2 AGREEMENTS ASSOCIATED WITH NANOMEDICINE PRODUCTS DEVELOPMENTS
4.3 RESTRAINTS
- 4.3.1 HIGH MANUFACTURING COST OF NANOMEDICINE
4.4 OPPORTUNITY
- 4.4.1 INCREASING NUMBER OF PIPELINE PRODUCTS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NANOMEDICINE MARKET

6 GLOBAL NANOMEDICINE MARKET, BY MODALITY

6.1 OVERVIEW
6.2 TREATMENTS
6.3 DIAGNOSTICS

7 GLOBAL NANOMEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 DRUG DELIVERY
7.3 DIAGNOSTIC IMAGING
7.4 VACCINES
7.5 REGENERATIVE MEDICINE
7.6 IMPLANTS

8 GLOBAL NANOMEDICINE MARKET, BY INDICATION

8.1 OVERVIEW
8.2 ONCOLOGICAL DISEASES
8.3 INFECTIOUS DISEASES
8.4 CARDIOVASCULAR DISEASES
8.5 ORTHOPEDIC DISEASES
8.6 NEUROLOGICAL DISEASES
8.7 UROLOGICAL DISEASES
8.8 OPHTHALMOLOGICAL DISEASES
8.9 IMMUNOLOGICAL DISEASES
8.10 OTHERS

9 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE

9.1 OVERVIEW
9.2 NANOPARTICLES
9.3 NANOSHELLS
9.4 NANOTUBES
9.5 NANODEVICES
- 9.5.1 ALBUMIN PARTICLES
- 9.5.2 INORGANIC NANOPARTICLES
- 9.5.3 LIPID NANOPARTICLE
- 9.5.4 LIPOSOMES
- 9.5.5 OTHERS

10 GLOBAL NANOMEDICINE MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 11.6.2 PARTNERSHIP/AGREEMENT/COLLABORATION

12 COMPANY PROFILES

12.1 SANOFI
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 JOHNSON & JOHNSON SERVICES, INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGY
12.3 PARVUS THERAPEUTICS INC.
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 NANOBIOTIX
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGY
12.5 ASCENDIA PHARMACEUTICAL
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGY
12.6 BRISTOL-MYERS SQUIBB COMPANY
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 JAZZ PHARMACEUTICALS
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 CYTIMMUNE SCIENCES, INC.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 NANOSPECTRA BIOSCIENCES
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 PFIZER INC
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES

13 DATA CITATIONS

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL NANOMEDICINE MARKET, FOR TREATMENTS, BY REGION, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTICS, BY REGION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL NANOMEDICINE MARKET, FOR DRUG DELIVERY, BY REGION, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTIC IMAGING, BY REGION, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL NANOMEDICINE MARKET, FOR VACCINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL NANOMEDICINE MARKET, FOR REGENERATIVE MEDICINE, BY REGION, 2019-2032 (USD BILLION)
TABLE 10 GLOBAL NANOMEDICINE MARKET, FOR IMPLANTS, BY REGION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 12 GLOBAL NANOMEDICINE MARKET, FOR ONCOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 13 GLOBAL NANOMEDICINE MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 14 GLOBAL NANOMEDICINE MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 15 GLOBAL NANOMEDICINE MARKET, FOR ORTHOPEDIC DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 16 GLOBAL NANOMEDICINE MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 17 GLOBAL NANOMEDICINE MARKET, FOR UROLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 18 GLOBAL NANOMEDICINE MARKET, FOR OPHTHALMOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 19 GLOBAL NANOMEDICINE MARKET, FOR IMMUNOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 20 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 21 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 22 GLOBAL NANOMEDICINE MARKET, FOR NANOPARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL NANOMEDICINE MARKET, FOR NANOSHELLS, BY REGION, 2019-2032 (USD BILLION)
TABLE 24 GLOBAL NANOMEDICINE MARKET, FOR NANOTUBES, BY REGION, 2019-2032 (USD BILLION)
TABLE 25 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY REGION, 2019-2032 (USD BILLION)
TABLE 26 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 27 GLOBAL NANOMEDICINE MARKET, FOR ALBUMIN PARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 28 GLOBAL NANOMEDICINE MARKET, FOR INORGANIC NANOPARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 29 GLOBAL NANOMEDICINE MARKET, FOR LIPID NANOPARTICLE, BY REGION, 2019-2032 (USD BILLION)
TABLE 30 GLOBAL NANOMEDICINE MARKET, FOR LIPOSOMES, BY REGION, 2019-2032 (USD BILLION)
TABLE 31 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 32 GLOBAL NANOMEDICINE MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 33 NORTH AMERICA: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 34 NORTH AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 35 NORTH AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 36 NORTH AMERICA: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 37 NORTH AMERICA: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 38 NORTH AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 39 US: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 40 US: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 41 US: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 42 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 43 US: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 44 CANADA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 45 CANADA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 46 CANADA: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 47 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 48 CANADA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 49 EUROPE: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 50 EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 51 EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 52 EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 53 EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 54 EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 55 GERMANY: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 56 GERMANY: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 57 GERMANY: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 58 GERMANY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 59 GERMANY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 60 FRANCE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 61 FRANCE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 62 FRANCE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 63 FRANCE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 64 FRANCE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 65 UK: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 66 UK: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 67 UK: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 68 UK: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 69 UK: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 70 ITALY: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 71 ITALY: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 72 ITALY: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 73 ITALY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 74 ITALY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 75 SPAIN: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 76 SPAIN: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 77 SPAIN: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 78 SPAIN: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 79 SPAIN: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 80 REST OF EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 81 REST OF EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 82 REST OF EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 83 REST OF EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 84 REST OF EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 85 ASIA-PACIFIC: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 86 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 87 ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 88 ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 89 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 90 ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 91 CHINA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 92 CHINA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 93 CHINA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 94 CHINA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 95 CHINA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 96 INDIA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 97 INDIA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 98 INDIA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 99 INDIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 100 INDIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 101 JAPAN: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 102 JAPAN: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 103 JAPAN: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 104 JAPAN: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 105 JAPAN: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 106 SOUTH KOREA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 107 SOUTH KOREA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 108 SOUTH KOREA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 109 SOUTH KOREA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 110 SOUTH KOREA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 111 AUSTRALIA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 112 AUSTRALIA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 113 AUSTRALIA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 114 AUSTRALIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 115 AUSTRALIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 116 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 117 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 118 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 119 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 120 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 121 REST OF THE WORLD: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 122 REST OF THE WORLD: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 123 REST OF THE WORLD: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 124 REST OF THE WORLD: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 125 REST OF THE WORLD: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 126 REST OF THE WORLD: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 127 MIDDLE EAST: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 128 MIDDLE EAST: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 129 MIDDLE EAST: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 130 MIDDLE EAST: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 131 MIDDLE EAST: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 132 AFRICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 133 AFRICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 134 AFRICA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 135 AFRICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 136 AFRICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 137 LATIN AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 138 LATIN AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 139 LATIN AMERICA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 140 LATIN AMERICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 141 LATIN AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 142 PUBLIC PLAYERS STOCK SUMMARY
TABLE 143 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 144 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 145 PARTNERSHIP/AGREEMENT/COLLABORATION
TABLE 146 SANOFI: PRODUCTS OFFERED
TABLE 147 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 148 PARVUS THERAPEUTICS INC.: PRODUCT OFFERED
TABLE 149 PARVUS THERAPEUTICS INC. KEY DEVELOPMENTS
TABLE 150 NANOBIOTIX: PRODUCTS OFFERED
TABLE 151 NANOBIOTIX: KEY DEVELOPMENTS
TABLE 152 ASCENDIA PHARMACEUTICAL: PRODUCTS OFFERED
TABLE 153 ASCENDIA PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 154 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 155 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 156 CYTIMMUNE SCIENCES, INC.: PRODUCTS OFFERED
TABLE 157 CYTIMMUNE SCIENCES, INC.: KEY DEVELOPMENTS
TABLE 158 NANOSPECTRA BIOSCIENCES: PRODCUTS OFFERED
TABLE 159 PFIZER INC: PRODUCT OFFERED
TABLE 160 PFIZER INC: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL NANOMEDICINE MARKET: STRUCTURE
FIGURE 2 GLOBAL NANOMEDICINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NANOMEDICINE MARKET
FIGURE 6 GLOBAL NANOMEDICINE MARKET, MODALITY SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 7 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2023 & 2032 (USD BILLION)
FIGURE 8 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MODALITY,
FIGURE 9 GLOBAL NANOMEDICINE MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 10 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2023 & 2032 (USD BILLION)
FIGURE 11 GLOBAL NANOMEDICINE MARKET SHARE (%), BY APPLICATION,
FIGURE 12 GLOBAL NANOMEDICINE MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 13 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2023 & 2032 (USD BILLION)
FIGURE 14 GLOBAL NANOMEDICINE MARKET SHARE (%), BY INDICATION,
FIGURE 15 GLOBAL NANOMEDICINE MARKET, MOLECULE TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 16 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2023 & 2032 (USD BILLION)
FIGURE 17 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MOLECULE TYPE,
FIGURE 18 GLOBAL NANOMEDICINE MARKET, BY REGION, 2023 & 2032 (USD BILLION)
FIGURE 19 GLOBAL NANOMEDICINE MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 21 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 22 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 23 EUROPE MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 24 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 25 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 27 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 28 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 30 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 31 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 1 NANOMEDICINE MARKET PLAYERS: COMPETITIVE ANALYSIS,
FIGURE 2 COMPETITOR DASHBOARD: NANOMEDICINE MARKET
FIGURE 3 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 4 SANOFI: SWOT ANALYSIS
FIGURE 5 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 6 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
FIGURE 7 NANOBIOTIX: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 8 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 9 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 10 JAZZ PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 11 JAZZ PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 12 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 PFIZER INC: SWOT ANALYSIS